Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Arcturus Therapeutics
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
September 03, 2024
From
Arcturus Therapeutics
Via
Business Wire
Tickers
ARCT
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
May 20, 2024
From
Arcturus Therapeutics
Via
Business Wire
Tickers
ARCT
ASX:CSL
CSLLY
OTC
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
February 05, 2024
From
Arcturus Therapeutics
Via
Business Wire
Tickers
ARCT
ASX:CSL
CSLLY
OTC
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
December 21, 2023
From
Arcturus Therapeutics
Via
Business Wire
Tickers
ARCT
ASX:CSL
CSLLY
OTC
Arcturus Therapeutics to Attend Upcoming Investor Conferences
August 17, 2023
From
Arcturus Therapeutics
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
August 14, 2023
From
Arcturus Therapeutics
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
April 27, 2022
From
Arcturus Therapeutics
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
February 16, 2022
From
Arcturus Therapeutics
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 21, 2022
From
Arcturus Therapeutics
Via
Business Wire
Tickers
ARCT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.